While Edgewise Therapeutics Inc has overperformed by 9.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EWTX rose by 60.04%, with highs and lows ranging from $38.12 to $14.90, whereas the simple moving average jumped by 7.69% in the last 200 days.
On January 22, 2025, Stifel started tracking Edgewise Therapeutics Inc (NASDAQ: EWTX) recommending Hold. A report published by Evercore ISI on November 22, 2024, Initiated its previous ‘Outperform’ rating for EWTX. Piper Sandler also rated EWTX shares as ‘Overweight’, setting a target price of $48 on the company’s shares in an initiating report dated March 07, 2024. Goldman August 25, 2022d its ‘Neutral’ rating to ‘Sell’ for EWTX, as published in its report on August 25, 2022. RBC Capital Mkts’s report from April 13, 2022 suggests a price prediction of $31 for EWTX shares, giving the stock a ‘Outperform’ rating. Goldman also rated the stock as ‘Neutral’.
Analysis of Edgewise Therapeutics Inc (EWTX)
To gain a thorough understanding of Edgewise Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -34.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.93, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and EWTX is recording an average volume of 980.55K. On a monthly basis, the volatility of the stock is set at 6.69%, whereas on a weekly basis, it is put at 7.25%, with a gain of 4.46% over the past seven days. Furthermore, long-term investors anticipate a median target price of $47.12, showing growth from the present price of $26.71, which can serve as yet another indication of whether EWTX is worth investing in or should be passed over.
How Do You Analyze Edgewise Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 29.38%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 78.81% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
EWTX shares are owned by institutional investors to the tune of 78.81% at present.
